Skip to main content

Advertisement

Log in

‘IL-2Rα-biased’ IL-2 for cancer immunotherapy

  • Research Briefing
  • Published:

From Nature Cancer

View current issue Submit your manuscript

This study reveals the previously underappreciated roles of CD25 (IL-2 receptor subunit-α) in IL-2 biology and cancer immunotherapy and provides mechanistic insights into the rational design of more-effective IL-2-based therapeutic agents for cancer treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1: IL-2α-bias promotes antitumor immunity.

References

  1. Abbas, A. K., Trotta, E., Simeonov, D. R., Marson, A. & Bluestone, J. A. Revisiting IL-2: biology and therapeutic prospects. Sci. Immunol. 3, eaat1482 (2018). A review article that presents the dual and opposing functions of IL-2.

    Article  PubMed  Google Scholar 

  2. Hernandez, R., Põder, J., LaPorte, K. M. & Malek, T. R. Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat. Rev. Immunol. 22, 614–628 (2022). A review article summarizing the different approaches to engineering IL-2 analogs.

    Article  CAS  PubMed  Google Scholar 

  3. [No authors listed]. Bempeg failure unlikely to affect other IL2 drugs. Cancer Discov. 12, 1604–1605 (2022). This news-in-brief article reports the clinical failure of an engineered IL-2.

  4. Lowery, F. J. et al. Molecular signatures of antitumor neoantigen-reactive T cells from metastatic human cancers. Science 375, 877–884 (2022). This paper reports a new method of neoantigen-specific T cell receptor prediction.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gide, T. N. et al. Distinct immune cell populations define response to Anti-PD-1 monotherapy and Anti-PD-1/Anti-CTLA-4 combined therapy. Cancer cell 35, 238–255 (2019). This paper reports predictive biomarkers of anti-PD-1 responses in patients with melanoma.

    Article  CAS  PubMed  Google Scholar 

Download references

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This is a summary of: Wu, W. et al. IL-2Rα-biased agonist enhances antitumor immunity by invigorating tumor-infiltrating CD25+CD8+ T cells. Nat. Cancer https://doi.org/10.1038/s43018-023-00612-0 (2023).

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

‘IL-2Rα-biased’ IL-2 for cancer immunotherapy. Nat Cancer 4, 1222–1223 (2023). https://doi.org/10.1038/s43018-023-00613-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s43018-023-00613-z

  • Springer Nature America, Inc.

Navigation